Animal and human studies by scientists at Rockefeller University have for the first time generated data to suggest that an individual’s pre-existing genetic make-up may impact the likelihood of cancer progressing and metastasizing.
Conferences
Blocking tumor signals can hinder cancer’s spread
For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine.
Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma
Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.
Blocking tumor signals can hinder cancer’s spread
For most people who die of cancer, the spread of the initial tumor is to blame. “Metastasis is what kills most cancer patients," says Serge Fuchs, a professor in Penn’s School of Veterinary Medicine. “Yet there are not many, if any, drugs that specifically target metastatic processes."